In EOC, M-sEVs can transfer miRNA-223 to cancer cells to promote drug resistance by targeting the PTEN/PI3K/AKT pathway (Zhu et al., 2019a), while in breast carcinoma (BCC), miRNA-223 promotes the invasion of BCC cells through the Mef2c-β-catenin pathway (Yang et al., 2011). This evidence concerns the gene MEF2C and skin basal cell carcinoma.